Randomized trial finds CBD did not reduce severe behavioral problems

Cannabidiol for Severe Behavioral Problems in Youths With Intellectual Disability: A Randomized Clinical Trial.

JAMA pediatrics • • Highly Relevant
🤖

AI Summary

This randomized, double-blind, placebo-controlled clinical trial tested whether CBD could reduce severe behavioral problems in 131 children and adolescents aged 6 to 18 years with intellectual disability. Participants received CBD or placebo for 8 weeks, followed by a 4-week follow-up. The primary outcome was parent-reported irritability on the Aberrant Behavior Checklist.

At the end of treatment, irritability scores were similar in the CBD and placebo groups, and the trial concluded that CBD was not effective for these behavioral problems in this population. At least one adverse event was reported by a similar proportion of participants in each group. This is an abstract-based summary; the abstract does not establish effects in other populations, for other uses of CBD, or beyond the study period.

💡 Key Findings

1
In a randomized trial of 131 youths with intellectual disability, CBD did not reduce severe behavioral problems compared with placebo at the end of treatment.
High
95%
2
At least one adverse event occurred in a similar proportion of participants receiving CBD and placebo.
High
90%

📄 Original Abstract

IMPORTANCE: There is a high level of interest in cannabidiol (CBD) as treatment for severe behavioral problems in children with intellectual disabilities. Given the lack of evidence, clinical trials are needed to inform practice. OBJECTIVE: To investigate the efficacy of CBD to reduce severe behavioral problems in children and adolescents with intellectual disability. DESIGN, SETTING, AND PARTICIPANTS: This parallel design, double-blind placebo-controlled randomized clinical trial was conducted between May 11, 2021, and May 8, 2025. Participants were children and adolescents aged 6 to 18 years with an intellectual disability and severe behavioral problems from 3 children's hospitals in Australia: The Royal Children's Hospital in Melbourne, Monash Children's Hospital in Melbourne, and The Children's Hospital Westmead in Sydney. INTERVENTION: Participants were randomly assigned 1:1 to receive CBD isolate in oil (10 mg/kg/d) or placebo orally for 8 weeks, with a 4-week follow-up period. MAIN OUTCOME AND MEASURE: The primary outcome was parent-reported score on the Aberrant Behavior Checklist, Irritability (ABC-I) subscale assessed at the end of the 8-week maintenance phase. RESULTS: Of 131 participants randomized after exclusion of 1 participant randomized in error, 65 were in the CBD group and 66 were in the placebo group. Overall, mean (SD) age was 11.2 (3.1) years, and 98 participants (74.8%) were male. A total of 110 participants (84.0%) had comorbid autism. Primary outcome data were available for 61 participants in the CBD group and 63 in the placebo group. Mean (SD) ABC-I subscale scores at baseline were 32.2 (7.3) and 30.0 (6.3) in the CBD and placebo groups, respectively. Intention-to-treat analysis showed similar mean (SD) ABC-I subscale scores at the end of treatment: 21.7 (11.0) in the CBD group and 19.2 (10.7) in the placebo group (mean difference, 2.4; 95% CI, -1.5 to 6.3). A similar proportion of participants experienced at least 1 adverse event in the CBD group (41 [63.1%]) and the placebo group (40 [60.6%]). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, CBD was not effective in treating severe behavioral problems in youths with intellectual disability. The results suggest that CBD should not be used to treat severe behavioral problems in this population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04821856.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.